Balt

About Balt

Balt Group is a global leader in neurovascular solutions, collaborating with physicians for over 45 years to develop innovative medical devices. Their mission focuses on physician-inspired innovations and patient-focused solutions, expanding from neurovascular to peripheral vascular spaces with a commitment to sustainability and positive impact for people, planet, and patients.

Products & Services

Neurovascular Devices: Offers the world's broadest portfolio of medical devices for ischemic and hemorrhagic stroke.

Peripheral Embolization Products: Dedicated products addressing peripheral vascular needs.

Specialties

Neurovascular Interventions Stroke Treatment Peripheral Vascular Solutions

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Debt T: - FT: Debt	A: 383400000 MR: - FA: €355 million FAN: 383400000	D: 2024-12-20 FD: 2024-12-20	2 investors

Debt Latest

2024-12-20

$383.4M

2 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Pascal Girin

President & Chief Executive Officer

P

Paul Laquerre

Chief Financial Officer

J

Jeff Sachs

Chief Legal Officer

K

Katherine Oates

Chief of Staff

E

Eric Montalescot

Senior Vice President, Europe, Latin America, Middle East & Africa

F

Fred Gunderman

Senior Vice President, USA

View 10 more team members with Pro

Unlock Full Team Directory

Recent News

Balt Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised